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Introduction {#sec005}
============

Infectious complications remain a major issue in patients with hematological malignancy following chemotherapy or hematopoietic stem cell transplantation (HSCT). The key manifestation of infection is fever, although various noninfectious febrile episodes can also develop frequently. In HSCT patients, it is more complex to distinguish between infectious condition and aseptic causes of febrile events due to transplantation-related complications such as graft-versus-host disease, engraftment syndrome, thrombotic microangiopathy, and relapse of underlying diseases \[[@pone.0225765.ref001]\]. Early distinction of fever is needed to provide immediate antibiotic treatment. Therefore, in patients with suspicion of systemic bacterial infection, timely and adequate clinical decision making is important and blood culture is recommended \[[@pone.0225765.ref002]--[@pone.0225765.ref004]\].

C-reactive protein (CRP) and procalcitonin (PCT) are widely used biomarkers of infections. However, CRP levels are frequently increased in non-infectious complications. They show low specificity for infection, especially in patients with hematologic malignancies \[[@pone.0225765.ref005]--[@pone.0225765.ref008]\]. PCT is useful for the diagnosis of sepsis. In the presence of bacterial infection, PCT is rapidly produced by the C cells of the thyroid gland as well as several other cell type. PCT production is stimulated by two mechanisms, directly by bacterial endotoxins and lipopolysaccharides and indirectly by inflammatory mediators such as tumor necrosis factor-alpha, interleukin-6, interleukin-1 \[[@pone.0225765.ref009], [@pone.0225765.ref010]\]. It is known as a valuable biomarker for detecting bacterial infections with high specificity \[[@pone.0225765.ref001], [@pone.0225765.ref005], [@pone.0225765.ref006], [@pone.0225765.ref011]\]. Several studies have shown that PCT can discriminate etiologies of infection in patients with sepsis \[[@pone.0225765.ref012]--[@pone.0225765.ref014]\]. Koya et al. \[[@pone.0225765.ref001]\] have demonstrated that PCT could provide information for discriminating between bacterial or fungal infection and other causes. It could also predict patient's prognosis after HSCT \[[@pone.0225765.ref001], [@pone.0225765.ref010]\]. It has been also suggested that PCT could discriminate different etiologies of infection, namely Gram-positive cocci (GPC), Gram-negative bacilli (GNB), and fungus \[[@pone.0225765.ref015], [@pone.0225765.ref016]\]. However, whether PCT can discriminate bacterial infection from other etiologies of fever in patients with hematologic disorder remains controversial. In addition, studies about its usefulness and cut-off values for culture-positive bacteremia in large number of patients with hematologic malignancy are limited.

Thus, the objective of the present study was to retrospectively analyze 614 febrile episodes that developed in patients with hematologic malignancies and investigate diagnostic values of PCT and CRP in predicting systemic bacterial infection.

Materials and methods {#sec006}
=====================

Patients and clinical diagnosis {#sec007}
-------------------------------

Patients with hematological malignancies and febrile episode who were admitted to Seoul St. May's hospital between February 2017 and June 2017 were considered for inclusion. We included 614 febrile episodes from 551 patients who had all laboratory data for PCT, CRP, and serial results of blood culture at the same time of febrile event. Fever was defined as an axillary body temperature above 37.5°C. Only initial febrile events after non-fever period of 1 week were included. Bacterial infection was defined as positive result of blood culture for bacteria except for coagulase-negative staphylococci. This study was approved by Institutional Review Board (approval number: KC18RESI0526) of Seoul. St. Mary's hospital, Seoul, Korea. Informed consent was waived by the board because the present retrospective study was performed using medical records.

Febrile episodes were classified into four groups according to culture results: (1) culture-positive bacterial infection by Gram-positive cocci (GPC), (2) culture-positive bacterial infection by Gram-negative bacilli (GNB), (3) culture-positive fungal infection or positive-aspergillus antigen assay with clinical symptoms (Fungus), and (4) viral infection or a noninfectious etiology including underlying disease, tumor lysis syndrome, drug, immune reaction or GVHD (Others). Group (1) and group (2) were classified as bacteremia (+) episodes while group (3) and group (4) were classified as bacteremia (-) episodes. Mixed infections \[bacteremia (+) and culture-positive fungal infection (+)\] were excluded from analysis.

Laboratory tests {#sec008}
----------------

For each febrile episode, blood samples were collected within 24 hours after development of fever to measure serum PCT and CRP levels. Serum PCT levels were measured with fully automated chemiluminescent immunoassay using ADVIA Centaur B.R.A.H.M.S PCT (Siemens Healthcare Diagnostics, Berlin, Germany) according to the manufacturer's instructions. Serum CRP concentrations were measured using commercial turbidimetric immunoassay. Blood culture results were attained using a BACTEC FX automated blood culture system (Becton Dickinson, Sparks, MD, USA). When only one set of coagulase-negative staphylococci was detected, it was considered as contamination and a negative blood culture. Aspergillus antigen assay was performed using Platelia^™^ Aspergillus antigen immunoassay (Bio-Rad Laboratories, Marnes-la-Coquette, France).

Statistical analysis {#sec009}
--------------------

Results are described as median and range or 95% confidence interval (95% CI) for continuous variables. For categorical data, results are described as number and percentages. Comparisons were made using Chi-square test for categorical data and Mann-Whitney U test for non-normally distributed variables. Logistic regression analyses were used to determine independent variables predicting bacteremia in hematologic patients with febrile episode. Variables with *P* value \< 0.1 in univariate analysis were entered into logistic regression analysis using backward stepwise selection as described previously \[[@pone.0225765.ref017]\]. Diagnostic reliabilities of PCT and CRP for bacteremia were evaluated using receiver-operating characteristic (ROC) curve and area under the curve (AUC). Diagnostic accuracies including sensitivity and specificity were calculated using several cut-off levels. Optimal cutoff levels to detect bacteremia were determined using Youden's index. All analyses were conducted using SPSS software version 24.0 (IBM Corp., Armonk, NY, USA) and MedCalc version 19.0 (MedCalc, Mariakerke, Belgium). A *P* value of less than 0.05 was considered statistically significant.

Results {#sec010}
=======

Characteristics of febrile episodes {#sec011}
-----------------------------------

In patients with febrile episodes, leukemia (57.8%), including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML), was the most frequent diagnosis followed by lymphoma (18.6%). Of 614 febrile episodes, 325 (52.9%) episodes occurred in patients who underwent HSCT and 273 (44.5%) episodes happened in neutropenic period defined as absolute neutrophil count (ANC) \< 0.5 × 10^9^/L. The primary diagnoses of 325 HSCT patients were AML (n = 135), ALL (n = 75), lymphoma (n = 44), multiple myeloma (n = 44) and myelodysplastic syndrome (n = 17). Systemic bacterial infections were confirmed in 99 (16.1%) febrile episodes, including 38 (6.2%) GPC and 61 (9.9%) GNB infections. Non-bacterial infections were identified in 515 (83.9%) febrile episodes caused by fungal infection (n = 29, 4.7%), viral infection (n = 28, 4.6%) or other noninfectious etiology (n = 458, 74.6%). The virus infections belong to the cytomegalovirus (n = 19), Human herpes virus (n = 5) and influenza virus (n = 4). Noninfectious febrile etiologies included pulmonary complication (n = 113), local infection (n = 35), engraft syndrome (n = 13), enterocolitis (n = 11), graft versus host disease (n = 8), relapse (n = 8) and miscellaneous or unknown source (n = 270).

Characteristics of patients with bacteremia {#sec012}
-------------------------------------------

Among a total 614 febrile episodes, 99 (16.1%) events were from patients with systemic bacterial infection. Clinical features between patients with bacteremia and those without bacteremia were compared. Results are shown in [Table 1](#pone.0225765.t001){ref-type="table"}. Age or sex was not associated with bacteremia (*P* \> 0.05). Patients with underlying diseases of ALL and AML showed higher frequencies of bacteremia (*P* = 0.033 and *P* = 0.009, respectively). Of 99 febrile episodes with bacteremia, 65 episodes were from HSCT patients (20.0%, 65/325) and 34 episodes were from non-HSCT patients (11.8%, 34/289) (*P* = 0.006). In univariate logistic regression analysis, neutropenia, HSCT, PCT level, and CRP level were significantly associated with bacteremia (all *P* \< 0.05). Multivariate logistic regression analysis demonstrated that neutropenia and PCT level, but not CRP level, were significantly associated with bacteremia \[odd ratio (95% CI): 8.220 (4.645--14.549) for neutropenia (*P* \< 0.001) and 1.048 (1.025--1.071) for PCT (*P* \< 0.001)\].

10.1371/journal.pone.0225765.t001

###### Comparison of clinical features between bacteremia (+) and bacteremia (-) subgroups.

![](pone.0225765.t001){#pone.0225765.t001g}

  Characteristics                       Bacteremia (-) (n = 515)   Bacteremia (+) (n = 99)   P-value
  ------------------------------------- -------------------------- ------------------------- ---------
  Sex (Male), no (%)                    278 (54.0)                 49 (49.5)                 NS
  Age, median (range)                   54 (20--90)                54 (20--74)               NS
  Underlying disease, no (%)                                                                 
      ALL                               84 (16.3)                  25 (25.3)                 0.033
      AML                               169 (32.8)                 46 (46.5)                 0.009
      CML                               24 (4.7)                   7 (7.1)                   NS
      Lymphoma                          102 (19.8)                 12 (12.1)                 0.072
      MDS                               41 (8.0)                   1 (1.0)                   0.012
      MM                                73 (14.2)                  6 (6.1)                   0.027
      Others                            22 (4.3)                   2 (2.0)                   NS
  HSCT                                  260 (50.5)                 65 (65.7)                 0.006
      Allo-HSCT                         180 (69.2)                 57 (87.7)                 0.003
      Auto-HSCT                         80 (30.8)                  8 (12.3)                  
  ANC (x10^9^/L), mean/median (range)   3.88/1.52 (0--194.3)       0.81/0.00 (0--11.3)       \<0.001
  Neutropenia (+), no (%)               192 (37.3)                 81 (81.8)                 \<0.001
  PCT (ng/mL), median (95% CI)          0.20 (0.18--0.22)          0.49 (0.26--0.93)         \<0.001
  CRP (mg/L), median (95% CI)           58.0 (51.1--66.5)          76.6 (50.5--92.8)         0.036

ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ANC, absolute neutrophil count; CI, confidence interval; CML, chronic myeloid leukemia; CRP, C-reactive protein; HSCT, hematopoietic stem cell transplantation; MDS, myelodysplastic syndrome; MM, multiple myeloma; PCT, procalcitonin.

Results of PCT and CRP levels to detect bacteremia in neutropenic and non-neutropenic patients {#sec013}
----------------------------------------------------------------------------------------------

Ninety-nine systemic bacterial infection episodes showed higher PCT and CRP levels than nonbacterial events (PCT: 0.49 (0.26--0.93) ng/mL vs. 0.20 (0.18--0.22) ng/mL, *P* \< 0.001; CRP: 76.6 (50.5--92.8) mg/L vs. 58.0 (51.1--66.5) mg/L, *P* = 0.036) ([Fig 1](#pone.0225765.g001){ref-type="fig"}). PCT and CRP levels were further analyzed between the presence and absence of neutropenia. In 341 non-neutropenic febrile episodes, both PCT and CRP levels discriminated bacteremia from non-bacteremia (PCT: 0.97 (0.27--5.61) ng/mL vs. 0.20 (0.17--0.24) ng/mL, *P* \< 0.001; CRP: 146.1 (78.9--240.2) mg/L vs. 52.2 (46.4--62.0) mg/L, *P* \< 0.001). In 273 neutropenic febrile episodes, PCT levels were higher in bacteremia compared to those in non-bacteremia \[0.44 (0.19--0.78) ng/mL vs. 0.20 (0.18--0.22) ng/mL, P = 0.001\] whereas CRP levels were not significantly different between bacteremia and non-bacteremia \[59.7 (41.7--84.5) mg/L vs. 69.5 (54.6--79.0) mg/L, *P* = 0.994\] ([Fig 2](#pone.0225765.g002){ref-type="fig"}).

![**Comparison of PCT (left) and CRP (right) levels between bacteremia and non-bacteremia.** Ninety-nine systemic bacterial infection episodes (colored box) showed higher PCT and CRP levels than nonbacterial events \[median (95% CI) (PCT: 0.49 (0.26--0.93) ng/mL vs. 0.20 (0.18--0.22) ng/mL, *P* \< 0.001; CRP: 76.6 (50.5--92.8) mg/L vs. 58.0 (51.1--66.5) mg/L, *P* = 0.036)\] by Mann-Whitney U test.](pone.0225765.g001){#pone.0225765.g001}

![**Comparison of PCT (left) and CRP (right) levels between neutropenic and non-neutropenic patients.** PCT levels discriminated bacteremia (gray box) from non-bacteremia (white box) in both neutropenia (-) patients \[median (95% CI), 0.97 (0.27--5.61) ng/mL vs. 0.20 (0.17--0.24) ng/mL, *P* \< 0.001\] and neutropenia (+) patients \[0.44 (0.19--0.78) ng/mL vs. 0.20 (0.18--0.22) ng/mL, P = 0.001\]. CRP levels discriminated bacteremia (gray box) from non-bacteremia (white box) in neutropenia (-) patients \[146.1 (78.9--240.2) mg/L vs. 52.2 (46.4--62.0) mg/L, *P* \< 0.001)\], but CRP levels were not different between bacteremia and non-bacteremia in neutropenia (+) patients \[59.7 (41.7--84.5) mg/L vs. 69.5 (54.6--79.0) mg/L, *P* = 0.994\] by Mann-Whitney U test.](pone.0225765.g002){#pone.0225765.g002}

Results of PCT and CRP levels for bacteremia in HSCT and non-HSCT patients {#sec014}
--------------------------------------------------------------------------

PCT and CRP levels were separately evaluated in HSCT patients and non-HSCT patients. In 289 febrile episodes from non-HSCT patients, PCT and CRP levels were higher in 34 bacteremia cases than those in 255 non-bacteremia cases (PCT: 0.91 (0.27--5.51) ng/mL vs. 0.22 (0.18--0.28) ng/mL, *P* \< 0.001; CRP: 125.7 (91.3--159.8) mg/L vs. 67.4 (55.7--81.9) mg/L, *P* = 0.002). In 325 febrile episodes form HSCT patients, PCT levels were higher in bacteremia cases compared to those in non-bacteremia cases \[0.30 (0.18--0.58) ng/mL vs. 0.19 (0.16--0.22) ng/mL, *P* \< 0.001\] whereas CRP levels were not significantly different between bacteremia and non-bacteremia cases \[51.0 (39.5--78.4) mg/L vs. 49.3 (39.9--61.3) mg/L, *P* = 0.414\] ([Fig 3](#pone.0225765.g003){ref-type="fig"}). Neutropenia was more frequently found in HSCT patients than that in non-HSCT patients (186/325 (57.2%) vs. 87/289 (30.1%), *P* \< 0.001). However, HSCT was not an independent factor for bacteremia in multivariate logistic regression analysis.

![**Comparison of PCT (left) and CRP (right) levels between HSCT and non-HSCT.** PCT levels discriminated bacteremia (gray box) from non-bacteremia (white box) in both non-HSCT patient \[median (95% CI), 0.91 (0.27--5.51) ng/mL vs. 0.22 (0.18--0.28) ng/mL, *P* \< 0.001\] and HSCT patients \[0.30 (0.18--0.58) ng/mL vs. 0.19 (0.16--0.22) ng/mL, *P* \< 0.001\]. CRP levels discriminated bacteremia (gray box) from non-bacteremia (white box) in non-HSCT patient \[125.7 (91.3--159.8) mg/L vs. 67.4 (55.7--81.9) mg/L, *P* = 0.002\] but CRP levels were not different between bacteremia and non-bacteremia in HSCT patients \[51.0 (39.5--78.4) mg/L vs. 49.3 (39.9--61.3) mg/L, *P* = 0.414\] by Mann-Whitney U test.](pone.0225765.g003){#pone.0225765.g003}

Diagnostic accuracy of PCT and CRP for detecting bacteremia {#sec015}
-----------------------------------------------------------

ROC curves were generated for CRP and PCT levels to detect bacteremia in a total of 614 febrile episodes ([Fig 4A](#pone.0225765.g004){ref-type="fig"}), in non-neutropenic febrile episodes ([Fig 4B](#pone.0225765.g004){ref-type="fig"}), and in neutropenic febrile episodes ([Fig 4C](#pone.0225765.g004){ref-type="fig"}). In a total of 614 febrile episodes, the AUC of PCT was 0.651 (95% CI: 0.612--0.689) while that of CRP was 0.566 (95% CI: 0.526--0.606), with PCT showing higher diagnostic performance than CRP in pairwise comparison (*P* = 0.017). With a cut-off of 0.5 ng/mL, PCT showed sensitivity of 49.5% and specificity of 79.0%. CRP with a cut-off of 25 mg/L showed sensitivity of 79.8% and specificity of 29.3% ([Table 2](#pone.0225765.t002){ref-type="table"}). When we analyzed PCT and CRP levels in 341 non-neutropenic episodes, both PCT and CRP showed good diagnostic accuracies, with AUC of 0.757 (95% CI: 0.708--0.801) (88.9% sensitivity and 51.1% specificity using cut-off of 0.2 ng/mL) and 0.763 (95% CI: 0.714--0.807) (66.7% sensitivity and 73.7% specificity using cut-off of 100 mg/L), respectively. However, in 273 febrile neutropenia, only PCT discriminated bacteremia from non-bacterial infection (AUC: 0.624, 95% CI: 0.564--0.682) whereas CRP could not detect bacteremia (AUC: 0.500, 95% CI: 0.439--0.561, *P* \> 0.05). [Table 2](#pone.0225765.t002){ref-type="table"} shows sensitivity and specificity of CRP and PCT for detecting bacteremia at different cut-off values.

![**ROC curves of PCT and CRP for detecting bacteremia in total (a), non-neutropenic (b), and neutropenic (c) patients.** In a total of 614 febrile episodes (a), the AUC of PCT was 0.651 (95% CI: 0.612--0.689) while that of CRP was 0.566 (95% CI: 0.526--0.606). In 341 non-neutropenic episodes (b), PCT and CRP showed AUC of 0.757 (95% CI: 0.708--0.801) and 0.763 (95% CI: 0.714--0.807), respectively. In 273 febrile neutropenia (c), PCT discriminated bacteremia from non-bacterial infection (AUC: 0.624, 95% CI: 0.564--0.682) whereas CRP could not detect bacteremia (AUC: 0.500, 95% CI: 0.439--0.561, *P* \> 0.05).](pone.0225765.g004){#pone.0225765.g004}

10.1371/journal.pone.0225765.t002

###### Diagnostic values of PCT and CRP for bacteremia.

![](pone.0225765.t002){#pone.0225765.t002g}

                                             PCT    CRP                                                                                                
  ------------------------------------------ ------ ------ ------------------------------------------ ----------------------------------------- ------ ------
  All febrile episodes (n = 614)             0.1    86.9   22.9                                       25[\*](#t002fn001){ref-type="table-fn"}   79.8   29.3
  0.2                                        64.7   50.9   50                                         60.6                                      44.9   
  0.5[\*](#t002fn001){ref-type="table-fn"}   49.5   79.0   100                                        37.4                                      72.4   
  1.0                                        38.4   86.0   150                                        19.2                                      85.8   
  Non-neutropenic episodes (n = 341)         0.1    94.4   25.1                                       25                                        94.4   31.9
  0.2[\*](#t002fn001){ref-type="table-fn"}   88.9   51.1   50                                         94.4                                      47.1   
  0.5                                        61.1   74.6   100[\*](#t002fn001){ref-type="table-fn"}   66.7                                      73.7   
  1.0                                        44.4   83.9   150                                        44.4                                      87.3   
  Febrile neutropenia (n = 273)              0.1    85.2   19.3                                       25                                        NA     NA
  0.2                                        59.3   50.5   50                                         NA                                        NA     
  0.5[\*](#t002fn001){ref-type="table-fn"}   46.9   83.3   100                                        NA                                        NA     
  1.0                                        37.0   90.1   150                                        NA                                        NA     

\*optimal cut-off levels by Youden's index.

CRP, C-reactive protein; PCT, procalcitonin

PCT and CRP levels according to different etiologies of fever {#sec016}
-------------------------------------------------------------

PCT and CRP levels in four different febrile etiologies (38 GPC, 61 GNB, 29 fungus and 486 others etiologies) are shown in [Fig 5](#pone.0225765.g005){ref-type="fig"}. PCT levels were significantly higher in GNB infectious episodes than those in febrile episodes caused by fungal infection \[0.58 (95% CI: 0.26--1.61) vs. 0.22 (0.16--0.38), *P* = 0.047\] or other etiology \[0.58 (95% CI: 0.26--1.61) vs. 0.19 (0.17--0.22), *P* \< 0.001\]. Although bacteremia (+) patients had higher CRP levels than bacteremia (-) patients, CRP levels were not significantly different among the four groups (*P* \> 0.05). There were no significant differences in PCT or CRP level between Gram-positive and Gram-negative infectious episodes (P \> 0.05). Among identified GNBs including *Escherichia coli* (*E*. *coli*), Klebsiella species, and *Pseudomonas aeruginosa*, *E*. *coli* was the most frequently detected GNB. There was no significant difference in PCT level among causative GNB species.

![**Comparison of PCT (left) and CRP (right) levels among different etiologies of fever.** PCT levels were significantly higher in GNB infectious episodes (gray box) than those in febrile episodes caused by fungal infection \[median (95% CI), 0.58 (95% CI: 0.26--1.61) vs. 0.22 (0.16--0.38), P = 0.047\] or other etiology \[0.58 (95% CI: 0.26--1.61) vs. 0.19 (0.17--0.22), P \< 0.001\]. CRP levels were not significantly different among the four groups (P \> 0.05).](pone.0225765.g005){#pone.0225765.g005}

Discussion {#sec017}
==========

In hematological patients, early differentiation of fever would be of significance. This retrospective study was implemented to evaluate performances of PCT and CRP to detect bacteremia in 614 febrile episodes from patients with hematological malignancy. In the present study, bacteremia was defined as culture-positive bacterial infection in serial results of blood culture at febrile event, and finally, PCT had better diagnostic accuracy for bacteremia than CRP.

As a biomarker of inflammation, CRP has been widely used in clinical practice \[[@pone.0225765.ref006], [@pone.0225765.ref012], [@pone.0225765.ref018], [@pone.0225765.ref019]\]. However, it cannot adequately differentiate etiologies of fever in hematologic patients due to its low specificity \[[@pone.0225765.ref020]\]. Previous reports have shown that PCT has high specificity for bacterial infections, and PCT has been introduced into clinical use \[[@pone.0225765.ref021], [@pone.0225765.ref022]\]. Kim et al., reported that PCT showed better diagnostic value than CRP in febrile neutropenic patients with solid cancer \[[@pone.0225765.ref019]\]. Our study also confirmed that PCT had higher specificity than CRP in hematologic patients. This is consistent with a previous finding showing that PCT measurement has better diagnostic value than CRP in adult patients regardless of type of comorbidities \[[@pone.0225765.ref021]\].

Diagnostic utility of PCT in neutropenic patients remains controversial. Leukocytes are known to produce PCT and inflammatory cytokines released from leukocytes can mediate PCT production. Previous study has noted that PCT values greater than 0.5 ng/ml are less common in patients with neutropenia \[[@pone.0225765.ref023]\]. When we analyzed diagnostic accuracies of PCT and CRP in 273 febrile neutropenia, only PCT had diagnostic value (AUC of 0.624) with specificity of 83.3% using cut-off of 0.5 ng/mL. However, the sensitivity of PCT was relatively low (46.9%), consistent with results of a previous study demonstrating low sensitivity of PCT in febrile neutropenia \[[@pone.0225765.ref006]\]. Our data support previous results of Lima et al. \[[@pone.0225765.ref024]\] showing that PCT cut-off point of 0.5 ng/mL is correlated with bacteremia (sensitivity of 51.9% and specificity of 76.5%) in a randomized controlled trial enrolling 62 hematological adult patients who have febrile neutropenia. To obtain high sensitivity of PCT test, lower cut-off levels should be considered. Therefore, clinicians need to expect low PCT levels in patients with febrile neutropenia and utilize PCT to help them confirm bacteremia.

In HSCT patients, diagnostic values of PCT and CRP for detecting infections are controversial, and previous studies have focused on different target populations \[[@pone.0225765.ref001], [@pone.0225765.ref006], [@pone.0225765.ref008], [@pone.0225765.ref025]\]. A meta-analysis by Lyu et al. \[[@pone.0225765.ref026]\] has concluded that PCT has only a moderate diagnostic value in discriminating infection from other inflammatory complications following allogeneic HSCT. Mori et al. \[[@pone.0225765.ref006]\] have shown that CRP is a better indicator for infections than PCT in HSCT while PCT is a better diagnostic marker for infections than CRP in non-HSCT. Several studies have also suggested that HSCT-related complications including GVHD and immune reaction can induce PCT positivity by stimulating mononuclear cells to produce inflammatory cytokines such as TNF-α \[[@pone.0225765.ref027]\]. In the present study, only PCT showed diagnostic value for detecting bacteremia in HSCT patients. However, HSCT patients were associated with neutropenia while HSCT was not an independent factor for bacteremia in multivariate analysis.

In this study, we also aimed to evaluate whether serum PCT or CRP levels could differentiate infection etiologies in febrile patients with hematologic disorders. PCT levels, but not CRP levels, were significantly higher in patients with Gram-negative bacteremia than in patients with fungus or other non-bacterial etiology (*P* \< 0.05). Other non-bacterial etiologies included viral infection and immunosuppressant or underlying disease-related febrile episodes. In viral infections, high concentration of interferon-gamma can suppress PCT production. Consequently, high level of PCT can be used for supportive diagnosis of bacterial infection \[[@pone.0225765.ref028]\].

In the present study, there was no significant difference in PCT level between Gram-negative and Gram-positive bacteremia, consistent with results of previous studies \[[@pone.0225765.ref006], [@pone.0225765.ref029]\]. However, this finding is not consistent with results of previous studies reporting that greater increase in PCT level was observed in *Enterobacteriaceae* compared to that in nonfermentative GNB. Leli et al. \[[@pone.0225765.ref015]\] have proposed that infection caused by *Enterobacteriaceae* is not likely to be associated with PCT level [≤]{.ul} 3.1 ng/mL. They showed significant difference in PCT value in association with infection by nonfermentative GNB. Furthermore, Yan et al. \[[@pone.0225765.ref016]\] have reported that PCT could distinguish between different bacterial species and infection sites. In the present study, 31 (66.0%) of 47 bacteremia cases caused by *Enterobacteriaceae* showed PCT level ≤ 3.1 ng/mL and 20 episodes even showed PCT level \< 0.5 ng/mL. Although nonfermentative GNB cases had lower median PCT levels than cases caused by *Enterobacteriaceae*, PCT levels were not significantly different between *Enterobacteriaceae* and nonfermentative GNB cases. The relatively low median PCT level for *Enterobacteriaceae* in this study could be explained by characteristics of neutropenic patients. While Leli et al. \[[@pone.0225765.ref015]\] and Yan et al. \[[@pone.0225765.ref016]\] included septic patients with heterogeneous underlying diseases, our study was undertaken in patients with hematologic malignancy who tended to have neutropenia due to chemotherapy or HSCT.

This study has some limitations. In this retrospective study, we could not demonstrate PCT or CRP levels in association with clinical course, specific transplant-related complications, or response to antimicrobial therapy. As previous studies reported that PCT was useful in monitoring the response to the infection and to the treatment \[[@pone.0225765.ref001], [@pone.0225765.ref010]\], prognostic role of PCT needs to be further explored in a large, well-defined cohort study. Despite these limitations, the major strength of this study was that it demonstrated the diagnostic value of PCT with different cut-off levels for culture-based bacteremia in large number of patients including patients with febrile neutropenia. This study on the diagnostic accuracy of PCT and CRP for bacteremia in hematologic patients including patients with neutropenia or HSCT is one of the largest studies conducted up to date.

In summary, for febrile episodes from patients with hematologic malignancy, PCT was more valuable than CRP for discriminating between bacteremia and non-bacteremia independent of neutropenia. PCT in combination with clinical parameters should be considered to predict bacteremia in these patients. Further studies are needed to validate the cut-off level of PCT in patients with different conditions.

10.1371/journal.pone.0225765.r001
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We would appreciate receiving your revised manuscript by Nov 02 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Senthilnathan Palaniyandi, Ph.D

Academic Editor

PLOS ONE

Journal Requirements:

1\. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. Thank you for stating the following in the Financial Disclosure section:

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (NRF-2017R1A2B4011181), Republic of Korea.The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

We note that one or more of the authors are employed by a commercial company: EONE Laboratories.

1\. Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors\' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Please also include the following statement within your amended Funding Statement.

"The funder provided support in the form of salaries for authors \[insert relevant initials\], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section."

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

2\. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.  

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to  PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>) . If this adherence statement is not accurate and  there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The manuscript of Dr. Eun-Jee Oh. and its group by \`\` Serum procalcitonin as an independent diagnostic markers 1 of bacteremia in febril patients with hematologic malignancies\` entitle was studied.

\- The subject and experiment design was good.

Some question in manuscript should be answered:

1- What is the mechanism of infection or fever to induce increase of PCT level?

2- Fever is responsible to increase serum level of PCT or PCT is responsible for fever?

3- However, usually patients with malignant hematopoiesis disorder have fever and immune system of this kind of patient is not effective, therefore infection is as usual. May be the cause of increase serum level of PCT, were not be related to malignant hematopoiesis disorder.

The Authors find that the PCT serum level increase by malignant hematopoiesis disorder or transplantation, here we should consider to some question:

a- In other malignancies what is happened for PCT? It has been necessary to have data from other malignancy and discusses about that.

b- Is it possible PCT would be prognosis factor or treatment evaluated factor?

The discussion should be more and improve.

Reviewer \#2: The authors present an analysis of a large patient cohort with haematological diseases focusing on infection monitoring with laboratory test such as CRP and PCT in addition to microbiological examinations. However, the presentation of the data in its current form is poor, lacks clarity, important details and interpretation.

Major:

1\. It should be elaborated if there are overlaps between patients with hematology diagnosis and those that were treated by HSCT. What were the typical diagnoses for HSCT?

2\. More details should be provided about viral infections and non-infectious etiology: lines 145 and 146.

3\. Statements of lines 163 and 164 do not correspond with the numbers of Table 2.

4\. Figure legends in general must be substantially extended with additional details e.g. case numbers in the respective subgroups, rational and method of subgrouping, statistics employed etc. I do not clearly understand the difference between Figs 1 and 2, similarly the meaning of colour is also missing.

5\. In addition to the above deficiencies, in the context of Fig 5 (lines 239 through 248), respective case numbers are missing. There is an apparent discrepancy between CRP differences in earlier comparisons and the apparent similarities in these comparisons.

6\. The abstract should be completely rewritten. For me the line of study is unclear. In my opinion a single observation is arbitrarily emphasized as conclusion.

Minor: potential points of grammatical improvements

1\. Table 1 should be omitted, it is redundant relative to Table 2

2\. In Table 2 ANC value (median) \<0.01 is unlikely to be correct for Bacteriemia pos pts

3\. Table 2 abbreviations should be in alphabetical orde

4\. English proficiency should be further improved. Even myself, a non-English native, found several incorrectly worded phrases.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Response to Reviewers
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Serum procalcitonin as an independent diagnostic markers of bacteremia in febrile patients with hematologic malignancies

PLOS ONE

Reviewer \#1: The manuscript of Dr. Eun-Jee Oh. and its group by \`\` Serum procalcitonin as an independent diagnostic markers 1 of bacteremia in febril patients with hematologic malignancies\` entitle was studied.

\- The subject and experiment design was good.

Some question in manuscript should be answered:

1- What is the mechanism of infection or fever to induce increase of PCT level?

Answer and correction;

According to the reviewer\`s comment, we added the following sentence in line 63-67 as "PCT is useful for the diagnosis of sepsis. In the presence of bacterial infection, PCT is rapidly produced by the C cells of the thyroid gland as well as several other cell type. PCT production is stimulated by two mechanisms, directly by bacterial endotoxins and lipopolysaccharides and indirectly by inflammatory mediators such as tumor necrosis factor-alpha, interleukin-6, interleukin-1 \[9, 10\]"

2- Fever is responsible to increase serum level of PCT or PCT is responsible for fever?

Answer and correction;

Thank you for your careful review. PCT level increases as a result of endotoxins and/or cytokines, and fever happens as a systemic response to any kind of sources like infection or inflammation. Both fever and increase of PCT level might be the results of infection. We described that in introduction as "The key manifestation of infection is fever, although various noninfectious febrile episodes can also develop frequently. In HSCT patients, it is more complex to distinguish between infectious condition and aseptic causes of febrile events due to transplantation-related complications such as graft-versus-host disease, engraftment syndrome, thrombotic microangiopathy, and relapse of underlying diseases" line 51-56.

3- However, usually patients with malignant hematopoiesis disorder have fever and immune system of this kind of patient is not effective, therefore infection is as usual. May be the cause of increase serum level of PCT, were not be related to malignant hematopoiesis disorder.

The Authors find that the PCT serum level increase by malignant hematopoiesis disorder or transplantation, here we should consider to some question:

a- In other malignancies what is happened for PCT? It has been necessary to have data from other malignancy and discusses about that.

Answer and correction;

In solid cancer, similar results were observed. According to the reviewer's comments, we added that as "Previous reports have shown that PCT has high specificity for bacterial infections, and PCT has been introduced into clinical use \[21.22\]. Kim et al., reported that PCT showed better diagnostic value than CRP in febrile neutropenic patients with solid cancer \[19\]." in discussion, lines 282-285.

b- Is it possible PCT would be prognosis factor or treatment evaluated factor?

Answer and correction;

Although the present study did not evaluate the prognostic role of PCT, previous studies revealed the prognostic values of PCT in patients with hematologic malignancies. We described in introduction as "It could also predict patient's prognosis after HSCT \[1, 10\]." " in lines 71-72.

The discussion should be more and improve.

Answer and correction;

According to the reviewer's comments, we added description as "As previous studies reported that PCT was useful in monitoring the response to the infection and to the treatment \[1, 10\], prognostic role of PCT needs to be further explored in a large, well-defined cohort study." in lines 343-345.

Reviewer \#2: The authors present an analysis of a large patient cohort with haematological diseases focusing on infection monitoring with laboratory test such as CRP and PCT in addition to microbiological examinations. However, the presentation of the data in its current form is poor, lacks clarity, important details and interpretation.

Major:

1\. It should be elaborated if there are overlaps between patients with hematology diagnosis and those that were treated by HSCT. What were the typical diagnoses for HSCT?

Answer and correction;

Thank you for your careful review. According to the reviewer's comments, we added the that as "The primary diagnoses of 325 HSCT patients were AML (n=135), ALL (n=75), lymphoma (n=44), multiple myeloma (n=44) and myelodysplastic syndrome (n=17)." In lines 138-139.

2\. More details should be provided about viral infections and non-infectious etiology: lines 145 and 146.

Answer and correction;

According to the reviewer's comments, we added detailed diagnoses as "Non-bacterial infections were identified in 515 (83.9%) febrile episodes caused by fungal infection (n = 29, 4.7%), viral infection (n = 28, 4.6%) or other noninfectious etiology (n = 458, 74.6%). The virus infections belong to the cytomegalovirus (n = 19), Human herpes virus (n = 5) and influenza virus (n = 4). Noninfectious febrile etiologies included pulmonary complication (n = 113), included local infection (n = 35), engraft syndrome (n = 13), enterocolitis (n = 11), graft versus host disease (n = 8), relapse (n = 8) and miscellaneous or unknown source (n = 270)." in lines 141-147.

3\. Statements of lines 163 and 164 do not correspond with the numbers of Table 2.

Answer and correction;

According to the reviewer's comments, we changed the sentence into "Of 99 febrile episodes with bacteremia, 65 episodes were from HSCT patients (20.0%, 65/325) and 34 episodes were from non-HSCT patients (11.8%, 34/289) (P = 0.006)." in lines 156-158.

4\. Figure legends in general must be substantially extended with additional details e.g. case numbers in the respective subgroups, rational and method of subgrouping, statistics employed etc. I do not clearly understand the difference between Figs 1 and 2, similarly the meaning of colour is also missing.

Answer and correction;

According to the reviewer's comments, we changed figure legends as

" Fig 1. Comparison of PCT (left) and CRP (right) levels between bacteremia and non-bacteremia. Ninety-nine systemic bacterial infection episodes (colored box) showed higher PCT and CRP levels than nonbacterial events \[median (95% CI) (PCT: 0.49 (0.26 - 0.93) ng/mL vs. 0.20 (0.18 -- 0.22) ng/mL, P \< 0.001; CRP: 76.6 (50.5 -- 92.8) mg/L vs. 58.0 (51.1 -- 66.5) mg/L, P = 0.036)\] by Mann-Whitney U test.

Fig 2. Comparison of PCT (left) and CRP (right) levels between neutropenic and non-neutropenic patients. PCT levels discriminated bacteremia (gray box) from non-bacteremia (white box) in both neutropenia (-) patients \[median (95% CI), 0.97 (0.27 -- 5.61) ng/mL vs. 0.20 (0.17 -- 0.24) ng/mL, P \< 0.001\] and neutropenia (+) patients \[0.44 (0.19 -- 0.78) ng/mL vs. 0.20 (0.18 -- 0.22) ng/mL, P = 0.001\]. CRP levels discriminated bacteremia (gray box) from non-bacteremia (white box) in neutropenia (-) patients \[146.1 (78.9 -- 240.2) mg/L vs. 52.2 (46.4 -- 62.0) mg/L, P \< 0.001)\], but CRP levels were not different between bacteremia and non-bacteremia in neutropenia (+) patients \[59.7 (41.7 -84.5) mg/L vs. 69.5 (54.6 -- 79.0) mg/L, P = 0.994\] by Mann-Whitney U test." in lines 183-197.

"Fig 3. Comparison of PCT (left) and CRP (right) levels between HSCT and non-HSCT. PCT levels discriminated bacteremia (gray box) from non-bacteremia (white box) in both non-HSCT patient \[median (95% CI) 0.91 (0.27 -- 5.51) ng/mL vs. 0.22 (0.18 -- 0.28) ng/mL, P \< 0.001\] and HSCT patients \[0.30 (0.18 -- 0.58) ng/mL vs. 0.19 (0.16 -- 0.22) ng/mL, P \< 0.001\]. CRP levels discriminated bacteremia (gray box) from non-bacteremia (white box) in non-HSCT patient \[125.7 (91.3 -- 159.8) mg/L vs. 67.4 (55.7 -- 81.9) mg/L, P = 0.002\] but CRP levels were not different between bacteremia and non-bacteremia in HSCT patients \[51.0 (39.5 -- 78.4) mg/L vs. 49.3 (39.9 -- 61.3) mg/L, P = 0.414\] by Mann-Whitney U test." in lines214-222.

"Fig 4. ROC curves of PCT and CRP for detecting bacteremia in total (a), non-neutropenic (b), and neutropenic (c) patients. In a total of 614 febrile episodes (a), the AUC of PCT was 0.651 (95% CI: 0.612 -- 0.689) while that of CRP was 0.566 (95% CI: 0.526 -0.606). In 341 non-neutropenic episodes (b), PCT and CRP showed AUC of 0.757 (95% CI: 0.708-0.801) and 0.763 (95% CI: 0.714 -- 0.807), respectively. In 273 febrile neutropenia (c), PCT discriminated bacteremia from non-bacterial infection (AUC: 0.624, 95% CI: 0.564 - 0.682) whereas CRP could not detect bacteremia (AUC: 0.500, 95% CI: 0.439 -- 0.561, P \> 0.05)." in lines 241-248.

"Fig 5. Comparison of PCT (left) and CRP (right) levels among different etiologies of fever. PCT levels were significantly higher in GNB infectious episodes (gray box) than those in febrile episodes caused by fungal infection \[median (95% CI), 0.58 (95% CI: 0.26-1.61) vs. 0.22 (0.16 -- 0.38), P = 0.047\] or other etiology \[0.58 (95% CI: 0.26-1.61) vs. 0.19 (0.17 -- 0.22), P \< 0.001\]. CRP levels were not significantly different among the four groups (P \> 0.05)." in lines 267-272.

5\. In addition to the above deficiencies, in the context of Fig 5 (lines 239 through 248), respective case numbers are missing. There is an apparent discrepancy between CRP differences in earlier comparisons and the apparent similarities in these comparisons.

Answer and correction;

According to the reviewer's comments, case numbers are added in the context and figure as "PCT and CRP levels in four different febrile etiologies (38 GPC, 61 GNB, 29 fungus and 486 others etiologies) are shown in Figure 5." in lines 255-256 and figure 5.

We agree with reviewer\`s opinion. In Figure 1, CRP levels were higher in bacteremia (+) group compared to the bacteremia (-) group (P =0.036), However, when we compared the CRP levels among four groups \[GNP(+), GNB(+), fungus (+), others(+)\], there was no significant difference. In addition, there were no significant differences in PCT or CRP level between Gram-positive and Gram-negative infectious episodes (P \> 0.05). We clarified that as "Although bacteremia (+) patients had higher CRP levels than bacteremia (-) patients, CRP levels were not significantly different among the four groups (P \> 0.05). There were no significant differences in PCT or CRP level between Gram-positive and Gram-negative infectious episodes (P \> 0.05)." in lines 259-261.

6\. The abstract should be completely rewritten. For me the line of study is unclear. In my opinion a single observation is arbitrarily emphasized as conclusion.

Answer and correction;

Thanks for your comments. We tried our best to improve the manuscript and made some correction in abstract according to the reviewer's comments and emphasized in conclusion as "Conclusions: In this single-center observational study, PCT was more valuable than CRP for discriminating between bacteremia and non-bacteremia independent of neutropenia or HSCT."

Minor: potential points of grammatical improvements

1\. Table 1 should be omitted, it is redundant relative to Table 2

Answer and correction;

According to the reviewer's comments, table 1 in submitted manuscript was deleted.

2\. In Table 2 ANC value (median) \<0.01 is unlikely to be correct for Bacteremia pos pts

Answer and correction;

According to the reviewer's comments, we corrected that.

3\. Table 2 abbreviations should be in alphabetical order

Answer and correction;

According to the reviewer's comments, we corrected them in alphabetical order.

4\. English proficiency should be further improved. Even myself, a non-English native, found several incorrectly worded phrases.

Answer and correction;

We have undergone English edit procedure.

I hope the revised manuscript will better meet the requirements of the 'Plos one' for publication. I thank you again for the constructive review by the referee.

Eun-Jee Oh

###### 

Submitted filename: Response to reviewers \[PONE-D-19-16377\].docx

###### 

Click here for additional data file.

10.1371/journal.pone.0225765.r003

Decision Letter 1

Palaniyandi

Senthilnathan

Academic Editor

© 2019 Senthilnathan Palaniyandi

2019

Senthilnathan Palaniyandi

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

13 Nov 2019

Serum procalcitonin as an independent diagnostic markers of bacteremia in febrile patients with hematologic malignancies

PONE-D-19-16377R1

Dear Dr. Oh,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Senthilnathan Palaniyandi, Ph.D

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#2: The questions raised have been adequately answered and appropriate modifications have bben made to the text.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#2: No

10.1371/journal.pone.0225765.r004
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Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

20 Nov 2019

PONE-D-19-16377R1

Serum procalcitonin as an independent diagnostic markers of bacteremia in febrile patients with hematologic malignancies

Dear Dr. Oh:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Senthilnathan Palaniyandi

Academic Editor

PLOS ONE
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